|
Ingredion Incorporated, a leading global provider of ingredient solutions, announced that it has completed two strategic investments in India to expand into high-value pharmaceutical applications.
In order to serve pharma and nutraceuticals, the company partners with customers seeking functional material to enhance the performance of formulations and overcome their technical challenges.
“These investments are part of our strategy to expand our specialty pharmaceutical product portfolio to better serve our customers and diversify into high-value non-food adjacencies,” said Jim Zallie, president and CEO, Ingredion.
As a result of these strategic investments, the Company’s portfolio of functional excipients now includes binders, fillers, super disintegrants, lubricants, gelatine replacers for softgels, viscosifiers, encapsulation materials, and parenteral graded extrose. The company manufactures these highly functional materials under stringent pharma good manufacturing practices (GMPs) and supports its customers with regulatory expertise and collaborative technical support.
“Ingredion looks forward to partnering with pharma and nutraceutical formulators and helping them meet regulatory challenges, progress drug development, and identify emerging trends,” added Rana Kayal, global director, pharma & nutraceuticals, Ingredion.
During the third quarter of 2022, the company acquired Amishi Drugs & Chemicals (AD&C), headquartered in Ahmedabad, India, which manufactures super disintegrants, lubricants, and viscosifiers complementing its portfolio of starch, mannitol, and dextrose product offerings.
In the fourth quarter of 2022, the company secured a majority position in Mannitab Pharma Specialities, based out of Malegaon, India. Started by M B Sugars, a leading supplier of specialty sugars to the pharmaceutical industry in India, Mannitab produces spray-dried mannitol for direct compression. The company’s investment will further expand Mannitab’s manufacturing capacity and support global exports.
Ingredion Pharma Solutions include binders, fillers, super disintegrants, lubricants, gelatine replacers for softgel, emulsions for encapsulation, viscosifiers, and parenteral APIs. In line with current and emerging trends and regulations, the company is continuously transforming to combine cGMP facilities, regulatory assistance, worldwide presence, and collaborative technical support to be a trusted formulation problem-solving partner to its customers.
Mannitab Pharma Specialities Private Limited was incorporated in 2022, and the Mannitol division of M B Sugars was spun off into Mannitab Pharma Specialities. Mannitab Pharma Specialities will be leveraging the combined strengths of Ingredion and M B Sugars in expanding its reach and enhancing customer service.
|